Search results
Results from the WOW.Com Content Network
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Shares in Athersys, Inc. (ATHX) soared more than 20% in U.S. premarket trading after the biotech company announced that it was granted approval by the Food and Drug Administration (FDA) to start a ...
Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. [1]
Every investor in Athersys, Inc. ( NASDAQ:ATHX ) should be aware of the most powerful shareholder groups. Insiders...
AOL Mail welcomes Verizon customers to our safe and delightful email experience!